Subtype
High Grade Astrocytic Tumor
CI-CAN-00005503Explore in graph →
495 active trials2 approved drugs51 evidence items
- NCIt
- C102897
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005503Explore in graph →
Clinical trials
1,778 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03746080 | Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma | completed | Phase 2 | 21 | Lawrence D RechtOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT04209790 | Neoadjuvant Chemoradiation for Resectable Glioblastoma(NeoGlio) | terminated | Phase 2 | 2 | Geisinger ClinicOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT06855628 | Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM) | suspended | Phase 2 | 10 | Stanford UniversityOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT04373785 | NG101m Adjuvant Therapy in Glioblastoma Patients | not yet recruiting | Phase 1 / Phase 2 | 52 | NeuGATE TheranosticsINDUSTRY | 1 | Oct 21, 2025 | clinicaltrials |
| NCT06059690 | Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells | recruiting | Phase 1 / Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT05734560 | D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients | recruiting | Phase 1 / Phase 2 | 50 | Darell BignerOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT06439420 | CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial(CBT-I in PBT) | completed | Phase 2 | 70 | Virginia Commonwealth UniversityOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07193654 | Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread | recruiting | Phase 2 | 38 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05608395 | 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)(GlioMET) | completed | Phase 2 | 33 | Masaryk Memorial Cancer InstituteOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06835803 | Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial(ELITE-GBM) | recruiting | Phase 2 | 56 | Brigham and Women's HospitalOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT03347617 | Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma | terminated | Phase 2 | 52 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06102525 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma | recruiting | Phase 1 / Phase 2 | 43 | Rznomics, Inc.OTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03050736 | Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression | completed | Phase 2 | 29 | Kintara Therapeutics, Inc.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT01478178 | Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 55 | Kintara Therapeutics, Inc.INDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT02717962 | Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting | completed | Phase 2 | 118 | Kintara Therapeutics, Inc.INDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04863950 | Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma | recruiting | Phase 2 | 25 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT04587830 | ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme(GBM) | active not recruiting | Phase 2 | 100 | Polaris GroupINDUSTRY | 2 | Aug 26, 2025 | clinicaltrials |
| NCT07138001 | Phase 2 Clinical Trial of KH617 | not yet recruiting | Phase 2 | 60 | Sichuan Honghe Biotechnology Co., Ltd.INDUSTRY | 0 | Aug 22, 2025 | clinicaltrials |
| NCT04747145 | Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma | active not recruiting | Phase 2 | 38 | Medical College of WisconsinOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT04910022 | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 150 | Nerviano Medical SciencesINDUSTRY | 5 | Aug 19, 2025 | clinicaltrials |
| NCT06018363 | Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection | recruiting | Phase 1 / Phase 2 | 25 | Dushu Lake Hospital Affiliated to Soochow UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07130149 | Sonodynamic-Chemoradiotherapy Integration in Glioblastoma | enrolling by invitation | Phase 2 | 230 | Yingjuan ZhengOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT02327078 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | completed | Phase 1 / Phase 2 | 307 | Incyte CorporationINDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT07120620 | PriCoTTF Study: TTFields Before and During Radiotherapy for Newly Diagnosed Glioblastoma(PriCoTTF) | completed | Phase 1 / Phase 2 | 33 | Sied KebirOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT04388475 | Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma | completed | Phase 2 | 57 | Oblato, Inc.INDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT01931098 | Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03672721 | IA Carboplatin + Radiotherapy in Relapsing GBM | recruiting | Phase 1 / Phase 2 | 35 | Université de SherbrookeOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT04118036 | Abemaciclib + Pembrolizumab In Glioblastoma | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03018288 | Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) | terminated | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2025 | clinicaltrials |
| NCT06356883 | Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma | recruiting | Phase 2 | 120 | Université de SherbrookeOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT03137888 | Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma | completed | Phase 2 | 30 | Emory UniversityOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT05929495 | Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma | recruiting | Phase 2 | 25 | University of Milano BicoccaOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04523688 | Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma(Combi G-Vax) | recruiting | Phase 2 | 28 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05909618 | Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases(14) | recruiting | Phase 2 | 33 | Sheba Medical CenterOTHER_GOV | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT07047066 | A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma | not yet recruiting | Phase 2 | 30 | Tongji HospitalOTHER | 0 | Jul 2, 2025 | clinicaltrials |
| NCT02781792 | Temozolomide Chronotherapy for High Grade Glioma | completed | Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT02780024 | Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM | active not recruiting | Phase 2 | 50 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04765098 | Tamoxifen Versus Etoposide After First Recurrence in GBM Patients | recruiting | Phase 2 | 60 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04121455 | Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients(GLORIA) | active not recruiting | Phase 1 / Phase 2 | 117 | TME Pharma AGINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT04019262 | Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 2 | John FlickingerOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT04740190 | Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd(TAC-GReD) | completed | Phase 2 | 33 | The University of Hong KongOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT04406272 | VB-111 in Surgically Accessible Recurrent/Progressive GBM | terminated | Phase 2 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT02655601 | Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001(BMX-HGG) | completed | Phase 1 / Phase 2 | 177 | BioMimetix JV, LLCINDUSTRY | 1 | Jun 8, 2025 | clinicaltrials |
| NCT04051606 | Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT04479241 | LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma | completed | Phase 2 | 25 | Istari Oncology, Inc.INDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 14, 2025source: clinicaltrials